European Journal of Vascular & Endovascular Surgery
Volume 40, Issue 1 , Pages 17-26, July 2010

Telomere Length Dynamics in Vascular Disease: A Review

Vascular Surgery Group, Department of Cardiovascular Sciences, University of Leicester, Leicester LE2 7LX, United Kingdom

Received 3 March 2010; accepted 26 April 2010. published online 24 May 2010.

Article Outline

Abstract 

Introduction

Telomeres are specialised DNA-protein complexes which cap the ends of linear chromosomes serving to maintain DNA integrity during cell division. Telomere length naturally shortens with successive cell divisions and represents a cellular marker of biological age. This paper aims to provide an overview of telomere biology and review the evidence for any association between vascular surgical conditions and short telomere length.

Methods

A systematic review of the literature was performed using the search terms ‘telomere’ and ‘vascular’.

Results

Considerable associations between a shorter mean telomere length and coronary heart disease have been observed. This finding extends to vascular disease risk factors including age, sex, smoking, obesity, hypertension and diabetes. Vascular diseases including abdominal aortic aneurysm, peripheral vascular disease and carotid disease were also associated with shorter telomere lengths but evidence was limited to a small number of studies. There were no reports of short telomere length associated with varicose veins or arterio-venous malformations suggesting a novel area for further investigation.

Conclusion

Multiple associations between short telomere length and vascular disease characterised by atherosclerosis suggest a possible link between telomere attrition and disease mechanisms. Further studies are warranted to validate and define the role of telomeres in vascular disease pathogenesis.

Keywords: Telomere, Telomerase, Vascular, Cardiac

 

Back to Article Outline

Introduction 

Telomeres are specialised DNA-protein complexes present at the ends of linear chromosomes in eukaryotes. They safeguard gene integrity during mitosis by preventing DNA degradation at chromosomal termini. Telomere length shortens with each cell division and can be likened to a ‘mitotic clock’ reflecting cellular turnover. This has given rise to concepts of telomere length as a surrogate marker of age at both the cellular level and organism level, as well as a potential biomarker of age-related diseases. Shortening of telomeres to a critical length induces ‘replicative senescence’ – the cessation of mitosis due to a finite number of cell divisions (the ‘Hayflick limit’). This mechanism appears to prevent genomic instability and development of malignancy in aged cells by limiting the number of cell divisions.1, 2 Studies relating to coronary heart disease have demonstrated short telomere length in peripheral blood leukocytes to be an independent risk factor for disease and potentially a superior predictor of disease onset than chronological age.3, 4 Furthermore, correlations between telomere lengths with specific stages of disease progression observed in cancer studies have revealed their potential prognostic and diagnostic value. The aim of this review was to determine whether this evidence exists for vascular conditions including aortic aneurysms and carotid artery disease.

Back to Article Outline

Methods 

The Medline and Embase databases were searched from 1965 to October 2009 using the search terms ‘telomere’ and ‘vascular’ and limits ‘English language’ and ‘Human’. Additional articles were obtained manually from reference lists and the latest ‘Telomere Biology’ supplement in Nature.5 Articles were screened as per PRISMA guidelines (Fig. 1).6 Sixty-nine articles were included in the final qualitative synthesis. Following an overview of telomere biology, we present salient findings from the literature under subheadings pertaining to different vascular conditions.

  • View full-size image.
  • Figure 1 

    Literature search flow diagram as per PRISMA guidelines.6 *Excluded papers included those relevant only to non-vascular disciplines including haematology and immunology. **Largely reviews that had been expanded upon by more recent work.

Telomere biology 

Structure and function 

Telomeres confer a protective role for each chromosome by preventing enzymatic erosion, non-homologous recombination and end–end fusion of chromosomal DNA. Such events can induce chromosomal instability, apoptosis and cell death.7 Human telomeres consist of three components, (i) tandem repeats of guanine-rich non-coding DNA sequences, predominantly TTAGGG in 5′–3′ direction, (ii) shelterin- a complex of six proteins adherent to telomeric DNA and (iii) telomerase, a DNA polymerase.7, 8, 9 Telomeres are arranged in to duplex loops which comprise a double-stranded telomere loop (T-loop) and a single-stranded (D-loop) (Fig. 2).2, 8, 9 Proteins forming the ‘shelterin complex’ bind to and protect the duplex loop. They prevent false recognition of telomeres as double-stranded DNA breaks which would otherwise be vulnerable to aberrant processing by DNA repair complexes.10 The two major shelterin proteins TRF-1 and TRF-2 (telomere repeat-binding factors) possess binding domains with high specificity for the telomere-repeat sequences explaining why shelterin is abundant at chromosome ends. TRF-1 is involved in telomeric DNA remodeling and negative regulation of telomere length.8 The removal of TRF2 initiates DNA damage repair pathways which can result in deleterious fusion of chromosomal ends. Human repressor activator protein (hRAP1) is a binding-partner of TRF2 and can extend telomeres when overexpressed.11 TRF1-interacting protein 2 (TIN2) is thought to mediate TRF1 activity and collectively both can inhibit DNA lengthening by telomerase. The two remaining shelterin proteins, pot-1 (protection of telomeres) and tpp1 (tripeptidyl peptidase I) are binding partners thought to both augment and inhibit telomerase function.12 Unlike the shelterin proteins which constantly reside at the telomere, numerous non-shelterin accessory proteins are intermittently recruited to the telomere and thought to influence telomere length control and repression of the DNA damage response. Examples include tankyrase (tank-1, tank-2) which may release TRF1 from the telomere and cause DNA elongation.13 In addition, Ku protein, a heterodimer of 2 polypeptides – Ku70 and Ku80, is integral to the non-homologous end-joining DNA repair pathway which is important to telomere maintenance.14 Knockout studies of the KU86 gene have shown human cell lines to exhibit higher rates of double-stranded DNA breaks and telomere loss culminating in cell death.15 Telomerase synthesizes telomeric DNA and prevents telomere attrition (erosion). It is integral to telomere maintenance and regulates cellular lifespan.16 Whilst absent in most somatic cells, low levels exist in highly proliferative cell lines including skin and intestinal mucosa.1, 17 Conversely, telomerase expression is upregulated in germline, embryonic and stem cells and more so in human cancer cells, contributing to cell immortalisation.16, 17, 18 Telomerase is composed of an RNA component (TERC) which serves as a template for DNA synthesis and a reverse transcriptase (TERT) which catalyses the elongation.17 Mutations and overexpression of these subunits may have pathological implications having been observed in conditions involving stem-cell failure, idiopathic pulmonary fibrosis and carcinogenesis.19

  • View full-size image.
  • Figure 2 

    The duplex structure of a telomere consisting of DNA forming a T-loop and D-loop. Several shelterin proteins bind specifically to the telomeric DNA and facilitate telomere end protection and length control.2 Shelterin complex core proteins- TRF1, 2 – Telomeric repeat-binding factors; RAP1-Human repressor activator protein 1; TIN2 – TRF1–interacting protein; Accessory Binding proteins- Ku- the Ku70/Ku86 heterodimer, tank-1,tank-2- tankyrase; MRE11/RAD50/NBS1-MRN DNA detection and repair complex, hnRNPs – heterogeneous nuclear ribonucleoprotein67.

Telomere length and assessment 

Each round of DNA replication results in a shorter telomere by 30–100 nucleotides.12 This is consequential of the ‘end replication problem’ that arises from the inability of DNA polymerase to replicate the 5′ end of the lagging strand after degradation of an RNA primer (Fig. 3).20 This loss of telomeric DNA can be regenerated by telomerase. Human telomere length varies between tissues from 12 to 16 kilobase (kb) pairs in comparison to 20–50 in mice.8, 14, 21 It may vary between chromosomes belonging to the same cell and between individuals of the same age.22, 23 During intrauterine life till birth however, telomere length appears to be consistent between leukocytes, liver, lung, muscle and myocardium.22, 23, 24 Loss of this synchrony in adulthood may be attributable to variable cellular proliferation rates as one matures. Indeed, it is evident that the rate of telomere attrition varies in different tissues, and accounts for 30–150 bp loss per annum (Table 1).21, 22, 23, 25, 26, 27, 28, 29, 30 Strong associations observed between peripheral blood leukocyte (PBL) telomere length in fathers and their children, may suggest paternal inheritance.31 Women’s telomeres have been reported to be 3.5% longer than men’s after adjustment for age in one study (n = 143).32 Despite similar PBL telomere lengths in newborn males and females, age-dependent telomere attrition occurs at a higher rate in males.23 However, beyond the age of 60 there is no such difference and women maintain longer telomeres into old age.33 However, others could not replicate these gender differences in PBL telomere length in elderly cohorts (79 years).24, 27 Telomere length is thus far considered an emerging marker of cellular ageing and age-related disease and has been measured by an array of techniques, most commonly by Southern Blot analysis of terminal restriction fragments (TRF). Other techniques including hybridization protection assays and fluorescence in situ hybridization are gaining popularity (Table 2).8 Evidence of shortened tissue telomere length patterns observed in both malignant and benign diseases including colorectal carcinoma, colonic polyps and gastric adenomas have revealed their potential value as biomarkers.26, 34, 35

  • View full-size image.
  • Figure 3 

    Illustration of the ‘end replication problem’ during unidirectional DNA replication. 1. Double stranded DNA ‘unzips’ in to a replication fork to allow DNA polymerase to synthesize in the 5′→ 3′ direction. 2. Leading strand is straightforwardly synthesized as continuous DNA from parental DNA. 3. Lagging strand can only be synthesized in discontinuous fragments with requirement of a primer. 4. Gap left by primer removal at the chromosomal terminus (telomere) cannot be repaired.12

Table 1. Comparison of telomere attrition (erosion) rates between vascular tissues and non-vascular tissue14, 16, 17, 18, 19, 20, 21.
Tissue type (healthy tissue unless specified)Attrition rate (mean base pair loss/year)nAge ranges (years)p-value of regression
Vascular tissues
‘Peripheral blood’-cell type not given26334720–85<0.001
Peripheral blood leukocytes2831123 twins2–95<0.005
Iliac arteries intima27102 ± 13 (SD)421–580.03
Internal thoracic artery intima874Not given0.06
Iliac vein endothelium (non-diseased autopsy specimens)47 ± 4 (SD)514–49Not given
Myocardium23 (Non-diseased autopsy specimens)Not given1680–1040.17
Non-vascular tissues
Oesophageal mucosa23601770–102Not given
Thyroid2591460–98<0.0001
Parathyroid (normal operative and autopsy specimens)92210–83<0.0001
Large Bowel Mucosa29 (matched normal mucosa from colorectal Ca patients-operative specimens)591290–9<0.0001
Hepatic30 (non-diseased autopsy specimens)55940–101<0.0001
Table 2. Summary of telomere measurement techniques in practice.
TechniquePrinciplesMeritsLimitations
Southern Blot analysis of terminal restriction fragments8Genomic DNA is digested by restriction enzymes in to fragments which are separated by electrophoresis. These are hybridized to labelled probes specific for telomere sequences. The hybridized terminal restriction fragments are quantified by densitometry and reflect an approximation of telomere length
Universal standard of comparison to newer methods

Provides mean telomere length of all chromosomes


Overestimates telomere length since includes subtelomeric sequences of unknown length

Labour intensive (∼5 days)

Requires pure unfragmented input DNA

Radiolabelling procedures unavoidable

Hybridization protection assays68Oligonucleotide probes labelled with a highly chemiluminescent acridinium ester specifically bind to telomere sequences. Resultant luminometer readings allow quantification of telomere repeats
Mean telomere length obtained without including subtelomeric regions-more accurate than Southern blotting

Less stringent input DNA purity required

Expedient protocols (<1 h)

Radiolabelling procedures not required

Provides limited detail of telomere length at the chromosomal or cellular level
Fluorescence in situ hybridization (FISH)69Telomere repeat-specific peptide nucleic acid probes labelled with fluorescent dye emit signals quantifiable by digital imaging systems. Small sized probes allow effective cellular penetration
Allows precise telomere repeat number quantification in individual cells

Viable cells from culture required but only <30. Enhanced precision variants available e.g. quantitative-FISH


Labour intensive

High requirement for technical expertise

Flow cytometry FISH – ‘Flow-FISH’21FISH is supplemented by use of antibody staining i.e. 2 probes, which allows targeting of specific cell lines within a sample
Telomere length determination possible in single cells

High sensitivity, accuracy and reproducibility due to use of 2 probes


Moderate/high complexity protocols

∼30 h protocol

Large number of cells required

Quantitative-polymerase chain reaction (qPCR)8Oligonucleotide primers specifically anneal to telomere repeat sequences and allow amplification and quantification in a thermal cycler. Comparison to a single reference gene allow telomere length to be expressed as telomere repeat copy number/single gene copy number ratio
More rapid than Southern Blot and requires less input DNA

Multiplex high-throughput e.g. 384-well format protocols available – suitable for epidemiological studies

Provides a relative reading of telomere length as opposed to absolute telomere length – therefore difficulty comparing to other methods

Back to Article Outline

Telomere length and aortic disease 

Latest telomere studies suggest that biological ageing of the vasculature may play a role in abdominal aortic aneurysm aetiology. We implemented the Southern Blot technique to compare peripheral blood leukocyte (PBL) telomere length in abdominal aortic aneurysms (n = 190) with that in age-sex matched controls (n = 183).36, 37 Significantly shorter telomere length was detected in AAA, evident by a mean difference of 189 bp (95% CI 77 bp-301 bp, P = 0.005). This relationship persisted after controlling for confounding risk factors with multiple regression analysis. Individuals in the lowest quartile of mean telomere length exhibited a 2-fold risk of AAA relative to those with a mean telomere length in the highest quartile (odds ratio 2.30, 95% CI 1.28–4.13, P = 0.005). Secondly, our data demonstrated a significant negative correlation between AAA diameter and telomere length. Previously, Wilson et al. compared PBL ‘telomere content’ from AAA (n = 20, n = 12 controls) in a separate cohort of patients by qPCR.38 Significantly reduced telomere content was apparent in AAA against controls (0.82, SD 0.06 and 1.27, SD 0.10 respectively, p < 0.001). The mean telomere content of aneurysm wall biopsies was compared in these cases (obtained during elective AAA repair) with unmatched controls (normal cadaveric aorta). Telomeric DNA was reduced in AAA vs. controls after adjusting for age and gender (2.17, 95% CI 1.77–2.56 vs. 2.80, 95% CI 2.32–3.28, P < 0.05). Furthermore, significant positive correlation of PBL telomere content with tissue telomere content was apparent for both cases and controls (partial correlation coefficient 0.62, P < 0.001). This correlation suggests that such PBL telomere measurements hold potential as accessible markers of vascular ageing in the aorta, in individuals with or without aneurysmal disease. Earlier, Okuda et al. assessed the telomere length in biopsies from non-aneurysmal aorta against the severity of any atherosclerotic lesions present (n = 44).39 Although telomere length in distal aortic biopsies shortened as atherosclerotic grade increased, this association was not significant after adjustment for age (p = 0.06). The group did demonstrate however, a significantly higher rate of age-dependent telomere attrition in proximal aorta in comparison to distal aorta (intima p = 0.003, media p = 0.004). Although there is no obvious explanation for this, the authors suggest that local factors such as shear wall stress may influence such findings.

Back to Article Outline

Peripheral arterial disease and venous disease 

Leukocyte telomere length has been measured in patients with chronic heart failure, with or without other atherosclerotic manifestations including peripheral vascular disease (age 40–80, cases n = 620, controls n = 183).40 The presence or past history of peripheral vascular disease (PVD), defined as ‘claudication’, was an independent predictor of a short telomere length (age-adjusted regression, p = 0.001). The ambiguous definition of PVD however, requires cautious interpretation of results. These findings failed to be replicated by the prospective Cardiovascular Health Study (age >65, n = 419), where PVD was defined as an ABPI of <0.9.41 Twenty-two cases of PVD were identified (7.9 year follow-up) and did not correlate with a shorter leukocyte telomere length (p = 0.51). Zee et al. have conducted the only telomere study in venous disease.42 Leukocyte telomere length in men whom incidentally developed venous-thromboembolism (n = 108, DVT 60%, PE 40%) were compared with age–sex matched controls (n = 108). No significant difference in telomere length was detected between cases and controls (p = 0.62).

Back to Article Outline

Telomeres and carotid disease 

The Cardiovascular Health Study conducted ultrasound measurements of common carotid and internal carotid intima-media thickness (n = 419).41 Although shorter leukocyte telomere length was observed with increasing carotid stenosis, this failed to reach significance (p = 0.07). Benetos et al. compared leukocyte telomere length against incidence of carotid plaques in an exclusively hypertensive cohort (n = 163).43 Carotid plaques were detected by ultrasound in 73 patients (44%), whom collectively exhibited a significantly shorter telomere length than those without plaques (n = 90 controls, 8.21 kb vs. 8.43 kb, p = 0.03). There was no difference in mean lipid levels (HDL, LDL, total cholesterol) between the two groups and statistical significance remained after excluding fifty-five patients on lipid-reducing drugs. This suggests that a shorter leukocyte telomere length may be a superior predictor of carotid plaque development in hypertensive patients and questions the role of telomeres in plaque pathogenesis. Subsequently, Adaikalakoteswari et al. compared leukocyte telomere length in type-2 diabetics with (n = 30) or without evidence of carotid plaques and femoral plaques on ultrasound (n = 30).44 Telomere length was shorter in diabetics with plaques (5.39, SEM 0.2 kb) compared to those without (6.21, SEM 0.2 kb) and collectively these were significantly shorter than those of non-diabetic controls (8.7, SEM 0.5 kb). However, they have failed to specify what proportion of the group of ‘diabetics with plaques’ had either femoral or carotid plaques.

Back to Article Outline

Telomeres and vascular risk factors 

Hypertension and pulse pressure 

In the Framingham Heart Study, hypertensive male subjects (n = 171) exhibited significantly shorter age-adjusted leukocyte telomere length compared with their normotensive peers (n = 156).45 The Cardiovascular Health Study however, could not replicate this in a mixed male and female cohort (p = 0.82).41 Arterial pulse pressure widens with age since systolic pressure gradually rises and diastolic pressure plateaus. This prompted Jeanclos et al. to hypothesize that pulse pressure may represent a phenotype of biological age. They investigated leukocyte telomere length against pulse pressures in a twin population (n = 98 pairs).46 Significant inverse correlation of telomere length with pulse pressure was noted, suggesting those with shorter telomeres exhibit a wider pulse pressure (p = 0.0032). Two studies suggest that telomere shortening may occur in arterial segments susceptible to increased hemodynamic stress. Okuda et al. identified a higher telomere attrition rate in infrarenal aortic specimens relative to the proximal abdominal aorta (n = 51 matched biopsies).39 In addition, Chang and Harley showed iliac artery endothelial cells have shorter telomeres than those in internal thoracic arteries (n = 13 matched biopsies).27 These data collectively imply that shorter telomere length, associated with increased endothelial cell turnover, may be a consequence of higher shear stresses in the vasculature. Replacement of functional cells with senescent endothelial cells, a process accelerated by exposure to reactive oxygen species, has been implicated in the pathogenesis of atherosclerosis.27, 45, 47

Smoking, obesity and diabetes 

Valdes et al. reported that the mean leukocyte telomere length of obese women (BMI ≥ 30, n = 119) was found to be 240 bp shorter than in lean women (BMI ≤ 20, n = 85, p = 0.026).48 In turn, a cohort study of both sexes (n = 70, 57% female) demonstrated annual leukocyte telomere length to significantly fall in those with an increasing BMI, independent of age over a 10-year period (p ≤ 0.001).49 Valdes et al. demonstrated a dose-dependent relationship between leukocyte telomere shortening and smoking.48 Each pack-year smoked equated to loss of an additional 5 bp (18%) of the average yearly loss in age-adjusted telomere length. The dose-dependent effects of smoking were replicated by Morla et al. in a cohort of male smokers with and without COPD (50 smokers, 26 ‘never-smokers’).50 Telomere shortening correlated with cumulative exposure to tobacco, independent of concomitant COPD. These results may collectively implicate smoking and obesity with pro-ageing effects. However, these findings were not reproduced by two studies of elderly individuals which failed to correlate shorter telomeres with number of cigarettes smoked per day or total number of cigarettes smoked.51, 52 The mean ages of each cohort were considerably higher in these studies, at 81 (n = 812) and 79 (n = 598). Recent evidence of telomere instability in individuals over 85 years old may explain the discrepancies between these studies with dissimilar demographics.52 Studies on South Asian populations have shown shorter leukocyte telomere lengths in individuals affected by non-insulin dependent diabetes (NIDDM, n = 40) and impaired glucose tolerance (n = 30) compared to controls (n = 40).44, 53 Jeanclos et al. previously demonstrated the same findings for insulin dependent diabetes mellitus (IDDM) but not for NIDDM in Caucasian men (n = 54 vs. n = 106 controls).54 Others have shown association between short leukocyte telomeres and diabetes, fasting insulin and fasting glucose and higher attrition rates in increasing insulin resistance.41, 45, 49 Conversely, Sampson et al. could only demonstrate shorter telomere length specifically in monocytes, not lymphocytes, in those with NIDDM (n = 21) against controls (n = 29).55

Back to Article Outline

Telomeres and coronary heart disease 

Several studies have described short telomere length to carry predictive value for coronary heart disease (CHD) onset and CHD-specific mortality. The largest prospective study amongst these included that of Brouilette et al. whom detected shorter leukocyte telomere lengths in patients whom developed CHD compared to controls in a 4.9-year follow-up study (cases 484, controls 1058).3 The risk of developing CHD was doubled in patients with telomere lengths in the middle and lowest tertiles. Brouilette et al. had previously shown that telomere length in the lowest 2 quartiles carried at least a 2-fold risk of developing premature MI (203 cases, 180 controls).56 A prospective study following healthy individuals aged 60–97 years assessed the impact of baseline leukocyte telomere length on subsequent cause-specific mortality (n = 143).32 Individuals in the lower half of telomere length distribution displayed a 3.18-fold higher risk of CHD-specific mortality than those in the higher distribution. Comparable results have arisen from a ten-year prospective analysis of 419 individuals (aged ≤ 73).41 This revealed a 3-fold risk of myocardial infarction in those with shorter telomeres. Most recently (2008), replication of these results has been achieved by a larger prospective case-control study (337 cases, 337 controls), limited however, to an entirely male cohort.57 Starr et al. recruited 190 participants and found PBL telomere lengths were significantly shorter in patients symptomatic of CHD (n = 63) and those with ischaemic ECG changes (n = 75).58 Telomere length studies in coronary endothelium have been limited due to difficulty obtaining sufficient DNA from inherently small target vessels. However, Ogami et al. were able to compare telomeric DNA content in diseased coronary arteries (n = 11) against normal arteries from autopsy specimens (n = 22). Significantly lower telomere content existed in the group with diseased arteries.59

Back to Article Outline

Discussion 

Multiple studies support an association between short telomere length and increased predisposition to cardiovascular morbidity including myocardial infarction and hypertension. This association extends to vascular risk factors including obesity, smoking and diabetes. However, only a small sub-set of studies show direct-association with vascular surgical conditions such as aortic aneurysm, carotid stenosis and PVD (Table 3). The few studies contesting such associations involved exclusively elderly cohorts (>85 years). An explanation for the latter negative findings may include that telomere attrition may increase vascular disease risk up to a certain point, beyond which other risk factors including chronological age may invoke a greater additional risk.43 Aside from one study relating to venous thromboembolism, there were no telomere studies of venous disorders such as varicose veins and arterio-venous malformations suggesting a novel area for further investigation. Overall, the associations reported above suggest that premature vascular ageing and associated disease may potentially be discernable by a shorter telomere length. There remains insufficient evidence however, to validate this association and determine whether short telomeres are a cause or consequence of disease. Cellular senescence being a major feature of atherosclerotic plaques, lends support to the hypothesis that shorter telomeres may be linked to conditions characterised by atherosclerosis.60 Evidence of short telomeres with differential expression of senescence-associated markers exists in vascular smooth muscle cells (VSMC) derived from atherosclerotic plaque specimens compared to normal VSMC.61 Accelerated replacement of healthy tissue with senescent tissue may link telomere attrition to disease development since the senescent phenotype has been linked to endothelial dysfunction and plaque instability.60, 62 Other proposed mechanisms linking telomere attrition to vascular disease include; (1) oxidative DNA damage – particularly in the presence of smoking and hypertension (known states of high oxidative stress); (2) telomere attrition due to higher rates of leukocyte proliferation as part of a global inflammatory response accompanying atherosclerotic disease; (3) reduced telomerase activity; and (4) association of short leukocyte telomere length with elevated plasma homocysteine (a risk factor for vascular disease).60, 62, 63, 64, 65 Accurate delineation of true changes in telomere length will require prospective longitudinal studies where serial measurements are scaled against incidence and progression of vascular disease over time e.g. AAA incidence and rate of expansion. This requires standardised outcome measures of vascular morbidity such as objective angiographic evidence of PVD as opposed to subjective reports of claudication symptoms in previous studies. One such study in progress is the Asklepios Study, a population study prospectively monitoring leukocyte telomere length and onset of cardiovascular events in a disease-free cohort (n = 2524).66 Outcome measures of interest to vascular surgeons include detection of phenotypes including carotid and femoral stenosis as well as haemodynamic measures of vascular function. The non-specific modulation of telomere length by a multitude of modifiable and non-modifiable risk factors such as age, gender, smoking and obesity however, suggest a poor specificity and limited potential as a biomarker of disease.

Table 3. Summary of telomere length dynamic studies in vascular surgical disease and healthy vascular tissue.
Condition/tissueTelomere sourceTelomere measurementMain findingscases/controlsP-valueReference
AAALeukocytesTRF*-Southern Blot analysis
Reduced telomere length in AAA

Telomere shortening correlated with increasing AAA diameter

190/1830.005Atturu et al.36, 37
LeukocytesTelomere/genomic DNA ratio – qPCRReduced telomere content in AAA20/12<0.001Wilson et al.38
AAA proximal sac vs. healthy aortaTelomere shortening in AAA20/12<0.05
Atherosclerotic non-aneurysmal aortaMatched aortic intimal and medial biopsiesTRF – Southern Blot analysisIncreased telomere attrition rate in distal aorta vs. proximal aorta for both tunica intima and tunica media44/440.003Okuda et al.39
Peripheral vascular disease (PVD)LeukocytesTelomere to single reference gene (T/S) ratio – qPCRReduced telomere length in patients with chronic heart failure and claudication vs. those without claudication620/1830.001Van Der Haarst et al.40
LeukocytesTRF – Southern Blot analysisNo association between telomere length and PVD -ABPI <0.922/n/a0.51Fitzpatrick et al.41
Carotid diseaseLeukocytesTRF – Southern Blot analysisReduced telomere length in hypertensives with carotid plaques vs. those without plaques73/900.03Benetos et al.43
LeukocytesTRF – Southern Blot analysisReduced telomere length in type 2 diabetics with carotid and femoral plaques vs. those without plaques30/300.0001Adaikalakoteswari et al.44

*TRF– terminal restriction fragment.

Back to Article Outline

Conflict of interest 

None declared.

Back to Article Outline

References 

  1. Blackburn EH. Telomere states and cell fates. Nature. 2000;408:53–56
  2. Neumann AA, Reddel RR. Telomere maintenance and cancer – look, no telomerase. Nat Rev Cancer. 2002;2:879–884
  3. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369:107–114
  4. Samani NJ, Boultby R, Butler R, Thompson JR, Goodall AH. Telomere shortening in atherosclerosis. Lancet. 2001;358:472–473
  5. Nature . Telomere biology webfocus. Available from http://www.nature.com/nature/focus/telomerebiology/index.html2009;(20/01/2010)
  6. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535
  7. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503–514
  8. Lin KW, Yan J. The telomere length dynamic and methods of its assessment. J Cell Mol Med. 2005;9:977–989
  9. Minamino T, Miyauchi H, Yoshida T, Tateno K, Kunieda T, Komuro I. Vascular cell senescence and vascular aging. J Mol Cell Cardiol. 2004;36:175–183
  10. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100–2110
  11. O’Connor MS, Safari A, Liu D, Qin J, Songyang Z. The human Rap1 protein complex and modulation of telomere length. J Biol Chem. 2004;279:28585–28591
  12. Wang F, Podell ER, Zaug AJ, Yang Y, Baciu P, Cech TR, et al. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature. 2007;445:506–510
  13. Kanoh J, Ishikawa F. Composition and conservation of the telomeric complex. Cell Mol Life Sci. 2003;60:2295–2302
  14. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301–334
  15. Wang Y, Ghosh G, Hendrickson EA. Ku86 represses lethal telomere deletion events in human somatic cells. Proc Natl Acad Sci USA. 2009;106:12430–12435
  16. Chan SW, Blackburn EH. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin. Oncogene. 2002;21:553–563
  17. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002;66:407–425[table of contents]
  18. Box JA, Bunch JT, Tang W, Baumann P. Spliceosomal cleavage generates the 3′ end of telomerase RNA. Nature. 2008;456:910–914
  19. Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature. 2009;461:230–235
  20. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol. 1992;225:951–960
  21. Lansdorp PM, Verwoerd NP, van de Rijke FM, Dragowska V, Little MT, Dirks RW, et al. Heterogeneity in telomere length of human chromosomes. Hum Mol Genet. 1996;5:685–691
  22. Okuda K, Bardeguez A, Gardner JP, Rodriguez P, Ganesh V, Kimura M, et al. Telomere length in the newborn. Pediatr Res. 2002;52:377–381
  23. Takubo K, Izumiyama-Shimomura N, Honma N, Sawabe M, Arai T, Kato M, et al. Telomere lengths are characteristic in each human individual. Exp Gerontol. 2002;37:523–531
  24. Youngren K, Jeanclos E, Aviv H, Kimura M, Stock J, Hanna M, et al. Synchrony in telomere length of the human fetus. Hum Genet. 1998;102:640–643
  25. Kammori M, Nakamura K, Kawahara M, Mimura Y, Kaminishi M, Takubo K. Telomere shortening with aging in human thyroid and parathyroid tissue. Exp Gerontol. 2002;37:513–521
  26. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866–868
  27. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA. 1995;92:11190–11194
  28. Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet. 1994;55:876–882
  29. Nakamura K, Furugori E, Esaki Y, Arai T, Sawabe M, Okayasu I, et al. Correlation of telomere lengths in normal and cancers tissue in the large bowel. Cancer Lett. 2000;158:179–184
  30. Takubo K, Nakamura K, Izumiyama N, Furugori E, Sawabe M, Arai T, et al. Telomere shortening with aging in human liver. J Gerontol A Biol Sci Med Sci. 2000;55:B533–B536
  31. Njajou OT, Cawthon RM, Damcott CM, Wu SH, Ott S, Garant MJ, et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci USA. 2007;104:12135–12139
  32. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393–395
  33. Unryn BM, Cook LS, Riabowol KT. Paternal age is positively linked to telomere length of children. Aging Cell. 2005;4:97–101
  34. Kim HR, Kim YJ, Kim HJ, Kim SK, Lee JH. Telomere length changes in colorectal cancers and polyps. J Korean Med Sci. 2002;17:360–365
  35. Maruyama Y, Hanai H, Fujita M, Kaneko E. Telomere length and telomerase activity in carcinogenesis of the stomach. Jpn J Clin Oncol. 1997;27:216–220
  36. Atturu GBS, Bown MJ, Samani N, London NJ, Sayers R. Short leukocyte telomere length is associated with abdominal aortic aneurysm. Br J Surg. 2009;96
  37. Atturu G, Brouilette S, Samani NJ, London NJ, Sayers RD, Bown MJ. Short leukocyte telomere length is associated with Abdominal Aortic Aneurysm (AAA). Eur J Vasc Endovasc Surg. 2010;39:559–564
  38. Wilson WR, Herbert KE, Mistry Y, Stevens SE, Patel HR, Hastings RA, et al. Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J. 2008;29:2689–2694
  39. Okuda K, Khan MY, Skurnick J, Kimura M, Aviv H, Aviv A. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis. 2000;152:391–398
  40. van der Harst P, van der Steege G, de Boer RA, Voors AA, Hall AS, Mulder MJ, et al. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol. 2007;49:1459–1464
  41. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165:14–21
  42. Zee RY, Michaud SE, Ridker PM. Mean telomere length and risk of incident venous thromboembolism: a prospective, nested case-control approach. Clin Chim Acta. 2009;406:148–150
  43. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension. 2004;43:182–185
  44. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis. 2007;195:83–89
  45. Demissie S, Levy D, Benjamin EJ, Cupples LA, Gardner JP, Herbert A, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell. 2006;5:325–330
  46. Jeanclos E, Schork NJ, Kyvik KO, Kimura M, Skurnick JH, Aviv A. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension. 2000;36:195–200
  47. Erusalimsky JD, Kurz DJ. Cellular senescence in vivo: its relevance in ageing and cardiovascular disease. Exp Gerontol. 2005;40:634–642
  48. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366:662–664
  49. Gardner JP, Li S, Srinivasan SR, Chen W, Kimura M, Lu X, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111:2171–2177
  50. Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AG. Telomere shortening in smokers with and without COPD. Eur Respir J. 2006;27:525–528
  51. Bischoff C, Petersen HC, Graakjaer J, Andersen-Ranberg K, Vaupel JW, Bohr VA, et al. No association between telomere length and survival among the elderly and oldest old. Epidemiology. 2006;17:190–194
  52. Martin-Ruiz CM, Gussekloo J, van Heemst D, von Zglinicki T, Westendorp RG. Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study. Aging Cell. 2005;4:287–290
  53. Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian Type 2 diabetic patients. Diabet Med. 2005;22:1151–1156
  54. Jeanclos E, Krolewski A, Skurnick J, Kimura M, Aviv H, Warram JH, et al. Shortened telomere length in white blood cells of patients with IDDM. Diabetes. 1998;47:482–486
  55. Sampson MJ, Winterbone MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care. 2006;29:283–289
  56. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol. 2003;23:842–846
  57. Zee RY, Michaud SE, Germer S, Ridker PM. Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta. 2009;403:139–141
  58. Starr JM, McGurn B, Harris SE, Whalley LJ, Deary IJ, Shiels PG. Association between telomere length and heart disease in a narrow age cohort of older people. Exp Gerontol. 2007;42:571–573
  59. Ogami M, Ikura Y, Ohsawa M, Matsuo T, Kayo S, Yoshimi N, et al. Telomere shortening in human coronary artery diseases. Arterioscler Thromb Vasc Biol. 2004;24:546–550
  60. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002;105:1541–1544
  61. Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res. 2007;100:15–26
  62. Fuster JJ, Andres V. Telomere biology and cardiovascular disease. Circ Res. 2006;99:1167–1180
  63. Saretzki G, Von Zglinicki T. Replicative aging, telomeres, and oxidative stress. Ann N Y Acad Sci. 2002;959:24–29
  64. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res. 2006;99:156–164
  65. Richards JB, Valdes AM, Gardner JP, Kato BS, Siva A, Kimura M, et al. Homocysteine levels and leukocyte telomere length. Atherosclerosis. 2008;200:271–277
  66. Rietzschel ER, De Buyzere ML, Bekaert S, Segers P, De Bacquer D, Cooman L, et al. Rationale, design, methods and baseline characteristics of the Asklepios Study. Eur J Cardiovasc Prev Rehabil. 2007;14:179–191
  67. Zhang QS, Manche L, Xu RM, Krainer AR. hnRNP A1 associates with telomere ends and stimulates telomerase activity. RNA. 2006;12:1116–1128
  68. Nakamura Y, Hirose M, Matsuo H, Tsuyama N, Kamisango K, Ide T. Simple, rapid, quantitative, and sensitive detection of telomere repeats in cell lysate by a hybridization protection assay. Clin Chem. 1999;45:1718–1724
  69. Saldanha SN, Andrews LG, Tollefsbol TO. Assessment of telomere length and factors that contribute to its stability. Eur J Biochem. 2003;270:389–403

PII: S1078-5884(10)00274-1

doi:10.1016/j.ejvs.2010.04.012

European Journal of Vascular & Endovascular Surgery
Volume 40, Issue 1 , Pages 17-26, July 2010

Article Tools

* Image Usage & Resolution